Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Reverse share split and malaria commercialization

By Michael FriisHead of Equities
30.10.2024, 13.55
ExpreS2ion Biotech Holding

On 16 October 2024, ExpreS2ion Biotechnologies announced that the company had signed a term sheet with Serum Institute of India Private Limited (SIIPL), a leading global vaccine manufacturer, to commercialize malaria vaccines currently in Phase I and Phase II.

On 21 October 2024, a reverse share split of the company’s shares was resolved, whereby 40 existing shares would be consolidated into 1 share, which is effective today.

In connection with these announcements, we sat down with the company’s CEO Bent Frandsen to get more flavor on the news. Hear more about the potential partner on the malaria vaccines and the next steps, as well as the rationale behind carrying out a reverse share-split in the video. 

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis 13:53, 30 October 2024.

Recent videos

CM
Catena Media, Webcast, Q2'25
12.08.2025, 18.00 Catena Media
In
Inderes – Presentation of Q2 2025
12.08.2025, 13.30 Inderes
Ra
Raute, Q2'25
12.08.2025, 13.00 Raute
NTG
NTG – Præsentation af regnskabet for 2. kvartal 2025
12.08.2025, 13.00 NTG Nordic Transport Group
ISS
ISS – Præsentation af regnskabet for 2. kvartal 2025
12.08.2025, 11.30 ISS
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.